Official Title FASED (Footstool in Alleviating Symptoms of Evacuation Disorder)

Purpose

The purpose of this research study is to see if using a footstool can make it easier to have bowel movements in patients who suffer from chronic constipation. The participants will be given a free footstool to use. They will be asked to keep a record of their bowel symptoms and answer some surveys about their symptoms on a phone or computer. 

You will be in the study for approximately 12 weeks. This includes 2 weeks before you start using the footstool, followed by 8 weeks where you will be using the footstool and up to 2 weeks to complete your initial and final surveys. 

Could this study be right for you?

• At least 18 years old
• Able to understand English
• Symptoms such as feeling incompletely empty after a bowel movement, needing to strain a lot when having a bowel movement or needing to use maneuvers such as rocking one's body back and forth or using their finger to remove stool.

Age Range

18 - 99

Official Title Sex Differences in Pain Reports and Brain Activation in Older Adults with Alzheimer's Disease

Purpose

The purpose of this study is to examine how men and women with and without dementia might perceive and respond to pain or discomfort.

Participants may complete various questionnaires by phone or video conferencing once a week for up to 8 weeks with an optional MRI screening.

Could this study be right for you?

• Men and women aged 60 years or older
• Dementia or memory issues

Participants and their caregiver (if applicable) may complete only 1 day of the study, or they may complete as many as they would like for up to 8 days total.

Age Range

60 and up

Official Title A multicenter, randomized, double-blind, parallel group, placebo-controlled study to assess safety, tolerability, pharmacokinetics and pharmacodynamics of BI 764198 administered orally once daily for 12 weeks in patients with focal segmental glomerulosclerosis.

Purpose

The overall objective is to investigate to investigate how safe, how well tolerated, and how effective R3R01 is in treating uncontrolled proteinuria in patients with Alport syndrome and steroid-resistant Focal Segmental Glomerulosclerosis. All eligible participants will be enrolled to receive R3R01 over a treatment period of 12 weeks. The study will consist of 3 periods, including a screening period of 3 weeks, a treatment period of 12 weeks, and a follow up of period of 12 weeks.

Could this study be right for you?

You may be eligible to participate if:

• You are aged 18 years or older
• Female patients and female partners of male patients willing to not become pregnant for the duration of the study
• Have not had an organ transplant and/or on a organ transplant list
• Have high protein in urine Alport Syndrome (AS) specific:
• Have X-linked AS and autosomal recessive AS
• Confirmed diagnosis of AS by genetic testing or kidney biopsy
• Do not have another kidney disease
• FSGS specific:
• Not older than 75 years of age
• Primary Focal segmental glomerulosclerosis (FSGS) (not caused by other condition) that is confirmed by kidney biopsy or documentation of genetic mutation
• Steroid-resistance: previous steroid treatment without remission

Age Range

18 and up

Official Title "What do physicians know about intellectual disability?" Getting information to design better medical training

Purpose

The purpose of this study is to explore the physicians’ knowledge of intellectual disabilities (ID) and their medical training and practice. The information resulting from this study will help to design adequate interventions and training programs for medical students and physicians aimed to improve their ID knowledge and the health care services provided to patients with ID. This is an observational cross-sectional study of physicians in the US using an anonymous online survey. The entire survey has 156 items and will require 15-20 minutes to complete.

Could this study be right for you?

• You are an American medical resident, an attending physician, or a medical educator in any type of medical specialization, and
• You have or do not have experience with patients with intellectual disabilities

Age Range

24 and up

Official Title Laying the Groundwork for Personalized Medicine in Aphasia Therapy: Genetic and Cognitive Predictors of Restorative Treatment Response

Purpose

This NIH-funded project will investigate patient-specific factors that may influence response to therapy for language impairment after stroke, or aphasia. Results from this work will assist with better estimation of prognosis for stroke survivors with aphasia, which could empower patients and families to make more informed health care decisions about how to pursue the most appropriate rehabilitation services based on their unique characteristics, such as genetics, cognitive skills, and brain structure after stroke.

Could this study be right for you?

Participants must meet the following criteria:

• Native English speaker
• Able to have an MRI

Age Range

18 and up

Official Title A Hybrid Effectiveness-Implementation Trial to Improve Safe Driving among Teen Drivers with Traffic Violations

Purpose

The purpose of this study is to test the effects of an in-vehicle driving feedback technology, with and without parent training, on parent-teen communications as well as teens' risky driving behaviors, unsafe driving behaviors, and subsequent traffic violations.

Could this study be right for you?

In order to be eligible:

• You must be 16-18 years of age
• Need a valid State of Ohio driver's license (no learner's permit)
• Proof of car insurance
• Must drive more than one hour per week

Age Range

16 and up

Official Title Nitrous Oxide and Cortico-Limbic Function in Aggression (Laughing Gas Study or LGS).

Purpose

The purpose of this study is to see how laughing gas (nitrous oxide) changes brain activity in study participants with and without “anger issues”. Brain activity is measured by Magnetic Resonance Imaging.

The length of time you will be involved in this study will be 4-8 weeks.

Could this study be right for you?

• You are a medically healthy man or woman
• You are between the ages of 21 and 55 years of age
• Do not abuse alcohol or other drugs
• With a current history of “anger issues”
• Able to complete study sessions during the week

Age Range

21 and up

Official Title Booster Seats Interview

Purpose

To explore how parents make the decision on transitioning their children from booster seats to seat belts; what factors may influence parents’ decision on the transition.

Could this study be right for you?

Inclusion criteria:

• At least 18 years of age
• A parent or legal guardian who is responsible for transporting their child routinely
• Have a child who stopped using booster seats within 1 year prior to the interview date, and the child who made the transition must be the first child of the parent
• Drive with a child at least once per week
• In good general health
• Fluent in English

Age Range

20 and up

Official Title M16-046: A Phase 3b Multicenter, Randomized, Double-Blind, Double-Dummy, Active Controlled Study Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Adult Subjects with Moderate to Severe Atopic Dermatitis

Purpose

The purpose of this study is to compare the effectiveness and safety of upadacitinib (ABT-494) versus dupilumab for the treatment of adult subjects (18-75 years of age) with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.

Could this study be right for you?

• Subject must have chronic Atopic Dermatitis (AD) with onset at least 3 years prior to study participation
• Subject must have > or = 10% body surface area involvement of atopic dermatitis
• Subject must have had inadequate response to topical corticosteroids or topical calcineurin inhibitors within the past 6 months
• OR documented systemic treatment for AD within the past 6 months
• OR for whom topical treatments are otherwise medically inadvisable
• No prior exposure to any JAK inhibitor (e.g., ruxolitinib, tofacitinib, baricitinib, upadacitinib, PF-04965842, and filgotinib)
• No prior exposure to dupilumab

Age Range

18 and up

Official Title A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients with Severe or Very Severe Alopecia Areata (JAHO)

Purpose

The main reason for you to take part in this study is not to treat you for your condition but to help in answering the following research questions:
• Whether baricitinib is better than placebo in the treatment of patients with severe alopecia areata (AA)
• The safety of baricitinib and any side effects you may have when you take it.

Could this study be right for you?

• Are at least 18 years and ≤60 years for males (≤70 years of age for females) at the time of informed consent
• Are able to read, understand, and give documented (electronic or paper signature) informed consent
• Current AA episode of more than 6 months’ duration and hair loss encompassing ≥50% of the scalp
• No spontaneous improvement over the past 6 months

Age Range

18 and up